-+ 0.00%
-+ 0.00%
-+ 0.00%

Hims & Hers Health (HIMS) Could Be 88% Below Fair Value As Q3 Risks Mount

Simply Wall St·11/15/2026 02:33:12
Listen to the news

Hims & Hers Health (HIMS) is back under the microscope after its latest quarter paired a fresh net loss and subscriber decline with softer guidance, ongoing privacy lawsuits, and a closely watched partnership involving Lilly’s weight loss drugs.

Hims & Hers Health has swung from a very strong three year total shareholder return of about 164% to a 1 year total shareholder return that is down 46.6%. Recent Q3 results, softer guidance, privacy lawsuits, and the Lilly obesity drug deal have all contributed to a 7 day share price return that is down 24.1% and a year to date share price return that is down 41.0% at a recent price of US$19.73. This suggests that momentum has clearly faded as investors reassess both growth potential and legal risk.

Spot fresh momentum and potential turnarounds by lining up Hims & Hers Health against a curated 34 high quality undervalued stocks.

Bulls point to rapid top line growth and the Lilly partnership. Bears focus on fresh losses, lawsuits, and weaker guidance. Which side does Hims & Hers Health’s current valuation seem to reward?

Most Popular Narrative: 88.5% Undervalued

Against a last close of $19.73, the most followed narrative on Hims & Hers Health pins fair value at $171.19. This points to a steep implied discount based on that framework. According to Deep_Insights, an investor in the Simply Wall St Community who authored the narrative, the key question is whether the platform can justify this gap over time using a multi dimensional growth plan.

The thesis is not about one medication, one category or one quarter. It is about a company repeatedly following the same playbook while expanding its addressable market.

See why 85 investors see Hims & Hers Health as 88% undervalued.

Result: Fair Value of $171.19 (UNDERVALUED)

Still, privacy lawsuits and the recent subscriber decline could pressure Hims & Hers Health if legal outcomes or customer churn turn out worse than investors currently expect.

Find out about the key risks to this Hims & Hers Health narrative.

Next Steps

Mixed signals around Hims & Hers Health can be confusing, so move quickly. Review both the concerns and the upside, and weigh the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Hims & Hers Health?

You do not need to stop with Hims & Hers Health. Use the Simply Wall St screener to quickly surface fresh ideas that fit the kind of portfolio you want to build.